Skip to main content

Table 8 Further one way and multi way sensitivity analyses

From: Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

 

Benefit-cost ratio PCV13 vs. ‘PPV23

Benefit-cost ratio PCV13 vs. ‘no vaccination’

 

Only direct cost

Including indirect cost

Only direct cost

Including indirect cost

Base case

2.09 €

2.16 €

1.27 €

1.32 €

PCV13 revaccination according to current PPV23 adult vaccination recommendations in Germany [[15]]

2.97 €

3.11 €

1.08 €

1.14 €

Revaccination PCV13 not needed

16.74 €

17.26 €

2.81 €

2.92 €

Revaccination PCV13 every 5 years

0.97 €

1.00 €

0.75 €

0.78 €

Incidence for in- and outpatient CAP according to Schnoor et al.: -55% [[48]]

1.01 €

1.05 €

0.65 €

0.68 €

PPV23 effectiveness against IPD upper limit [[9]]

2.07 €

2.14 €

1.27 €

1.32 €

PPV23 effectiveness against IPD lower limit [[9]]

2.12 €

2.19 €

1.27 €

1.32 €

PPV23 effective in preventing inpatient CAP according to Maruyama et al. [[29]]: 45%

0.86 €

0.88 €

1.28 €

1.34 €

PCV13 ineffective in preventing in- and outpatient CAP

0.17 €

0.17 €

0.16 €

0.18 €

No indirect herd effects of PCV7 vaccination

2.51 €

2.60 €

1.54 €

1.61 €